Company research · Aspen Neuroscience
Aspen Neuroscience: Develops Autologous iPSC-Derived Cell Replacement Therapies for Neurodegenerative Diseases
The question
What is Aspen Neuroscience: what does it do, how big is it and how is it doing, who owns and funds it, who runs it, and how do the company and the press describe it?
The 14 searches GAR ran
- site:aspenneuroscience.com investor relations annual report 2025
- site:aspenneuroscience.com newsroom press release
- Aspen Neuroscience news 2026
- Aspen Neuroscience criticism controversy concerns
- Aspen Neuroscience company what it does products services
- Aspen Neuroscience company overview founded headquarters industry
- Aspen Neuroscience annual revenue employees 2025
- Aspen Neuroscience revenue profit results 2026
- Aspen Neuroscience funding round raised investors valuation
- Aspen Neuroscience owner parent company stock listing
- Aspen Neuroscience CEO founder leadership team
- Aspen Neuroscience chief executive executives board
- Aspen Neuroscience press release announcement 2026
- Aspen Neuroscience mission strategy statement
GAR’s answer
Aspen Neuroscience develops autologous induced pluripotent stem cell-derived cell replacement therapies for neurodegenerative diseases, including an investigational therapy for Parkinson's disease.
What we found
What it does
As of 2026, Aspen Neuroscience develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company operates within the biotechnology sector, with a specific emphasis on the treatment of Parkinson's disease. Its primary focus is on personalized cell therapy, including the development of ANPD001. This investigational therapy is a single-dose, autologous dopaminergic neuronal precursor cell (DANPC) treatment designed for Parkinson's disease. Aspen Neuroscience describes this as the world's first autologous iPSC-derived neuron replacement therapy for the condition. Beyond this lead candidate, the company advances additional cell replacement candidates. These include therapies targeting both sporadic and genetic forms of Parkinson's disease, as well as other candidates for conditions of the central nervous system (CNS). [9] [10] [11]
The numbers
Aspen Neuroscience operates a GMP facility that spans 22,000 square feet. This facility includes an additional 8,000 square feet designed to accommodate future automation. The company’s latest funding round was a Series C. The San Diego Business Journal’s 500 Most Influential People in San Diego list includes 500 individuals. [1] [10]
Funding and ownership
As of 2025, Aspen Neuroscience had raised a total of $387M in funding, according to data from caplight.com. The company’s most recent financing round was a Series C, also reported by caplight.com as of 2025. According to forgeglobal.com, the Series C round raised $115.62M at a price per share of $1.52, with these figures also dated as of 2025. No other funding rounds or ownership details are provided in the available facts. [12] [13]
| Metric (2025) | Value |
|---|---|
| Total Funding Raised | $387M [12] |
| Series C - Amount Raised | $115.62M [13] |
| Series C - Price per Share | $1.52 [13] |
Who runs it
Aspen Neuroscience is led by a management team that includes Damien McDevitt, who serves as Chief Executive Officer. Dalen Meeter holds the position of Chief Financial Officer. Kim Raineri is the Chief Technology Officer, while Lisa Johnson-Pratt serves as Chief Commercial Officer. The company also includes Silvia Michelazzi, who is the Senior Director of Business Development, and Mike Deridder, who is the Head of Commercial Strategy and Operations. [12] [14] [15] [16]
What the press says
Press reports from late October 2026 describe Aspen Neuroscience's initial public offering. Biopharmadive reported on October 29, 2026, that the company raised $140.6 million to advance its treatment into clinical testing, involving 9.4 million shares. Renaissance Capital noted on October 26, 2026, that the company set terms for a $150 million IPO, also citing 9.4 million shares. Yahoo Finance and BioSpace both reported on October 30, 2026, that gross proceeds were expected to be approximately $140.6 million, with a share price of $15.00. An earlier report from Pharmaphorum, dated 2020, stated that the gross proceeds of $140.6 million from the IPO would fund clinical testing of its one-shot treatment. [4] [5] [6] [7] [8]
Where the sources disagree
- Press view is repeated, never independently reported: $140.6 million appears on 4 hosts (pharmaphorum.com, uk.finance.yahoo.com, www.biopharmadive.com, www.biospace.com), none of them a primary source or a data publisher. [4] [6] [7] [8]
- What the company says. Asked, and the search found no public statement either way.
Analysis
Aspen Neuroscience is a biotechnology company focused on developing personalized cell therapies, specifically using autologous induced pluripotent stem cells (iPSCs) to treat neurodegenerative diseases like Parkinson's. [9] [10] [11]
The company’s lead product, ANPD001, is an investigational single-dose therapy designed to replace dopaminergic neurons in patients with Parkinson's disease. [9]
Aspen Neuroscience has raised a total of $387 million in funding, with its most recent round being a Series C that raised $115.62 million. [12] [13]
The company conducted an Initial Public Offering (IPO) with a share price of $15.00, offering 9.4 million shares to raise approximately $140.6 million for clinical testing. [4] [7]
Aspen Neuroscience operates a 22,000 square foot GMP facility that includes an additional 8,000 square feet reserved for future automation. [1]
The company is led by a management team including CEO Damien McDevitt, CFO Dalen Meeter, and CTO Kim Raineri. [12] [14] [15]
Strengths and concerns
Strengths
- Aspen Neuroscience raised $140.6 million in its IPO, providing capital to advance its treatment into deeper clinical testing. [4] [6] [7] [8]
- The company has secured a total of $387 million in funding, demonstrating sustained investor confidence in its cell therapy platform. [12]
- Aspen Neuroscience operates a 22,000 square foot GMP facility, which includes 8,000 square feet of additional space reserved for future automation. [1]
- The company is developing the world's first autologous iPSC-derived neuron replacement therapy for Parkinson's disease, positioning it as a pioneer in personalized cell therapy. [11]
Concerns
- The company’s entire pipeline is concentrated in a single disease area, Parkinson’s disease, meaning a failure in this specific therapeutic approach would eliminate its primary product candidate. [9] [10] [11]
- Aspen Neuroscience is pre-revenue and dependent on external capital, having raised a total of $387 million to date, with its most recent funding round being a Series C of $115.62 million. [10] [12] [13]
- The company’s IPO raised approximately $140.6 million, which is less than the $150 million target set in the terms, indicating a potential shortfall in the capital raised compared to initial expectations. [4] [5] [6]
- The company’s business model relies on a complex, personalized manufacturing process for autologous cell therapies, which carries inherent operational risks and high costs associated with producing individualized treatments for each patient. [1] [9] [11]
Sources
- Spotlight | Aspen Neuroscience
- Aspen Neuroscience (ASPE) Stock Price, Chart & News
- Aspen Neuroscience - Products, Competitors, Financials, Employees, Headquarters Locations
- Aspen Neuroscience, Inc. Asset Profile | Preqin | BlackRock
- Aspen Neuroscience Valuation & Funding History | Caplight
- Aspen Neuroscience IPO Timeline and Financing Details - Forge
- Board of Directors | Aspen Neuroscience
- Leadership | Aspen Neuroscience
- Aspen Neuroscience, Inc. Management Team | Org Chart
Researched and written by GAR, Octum’s cognitive engine, from the public sources listed above; every figure was checked automatically against the source it cites, and this version was reviewed by Octum before publication. First published 30 October 2026; updated 30 October 2026. Suggest a correction · Read as markdown